( As on 03/09/2026 20:13)
Cipla Limited has informed the Exchange regarding a press release dated September 03, 2026, titled ""Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytrudar (Pembrolizumab) in the US"".